Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
Cryo-Cell International, Inc. (Cryo-Cell) is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (Celle). This report covers the quarterly period ended May 31, 2011, and the six-month period ended May 31, 2011. The financial statements have been retrospectively adjusted to adopt a new accounting principle regarding revenue recognition for multiple deliverable arrangements.
Key Financial Metrics
| Metric | Six Months Ended May 31, 2011 | Six Months Ended May 31, 2010 |
|---|---|---|
| Total Revenue | $9,073,831 | $8,625,568 |
| Net Income | $410,848 | $758,344 |
| Operating Income | $1,315,964 | $1,571,666 |
| Net Cash Provided by Operating Activities | $238,538 | $526,102 |
| Cash and Cash Equivalents (End of Period) | $8,211,021 | $6,929,684 |
| Total Assets | $19,346,049 | $18,162,419 |
| Total Liabilities | $19,713,046 | $19,094,912 |
| Stockholders' Deficit | $(366,997) | $(932,493) |
Debt and Liquidity: The Company has no long-term indebtedness as of May 31, 2011. Liquidity is supported by cash balances of approximately $8.2 million and marketable securities of approximately $1.1 million. The Company anticipates these resources will be sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% year-over-year, driven by an 8% increase in processing and storage fees due to an 11% rise in specimens processed. This was partially offset by a 19% decrease in licensee income, attributed to the timing of non-recurring up-front license fee installments.
- Profitability Decline: Net income decreased 46% to $410,848. This decline was primarily caused by a 13% increase in marketing, general, and administrative expenses (due to legal fees, consulting, and advertising) and an 86% increase in research and development expenses related to the Celle technology.
- Cost of Sales: Increased 1% to $2.27 million, reflecting higher specimen processing volumes. However, cost of sales as a percentage of revenue improved slightly from 26% to 25%.
- Accounting Change: The Company retrospectively adopted a new accounting standard for revenue recognition, which adjusted prior period financials to allocate discounts ratably between processing and storage deliverables rather than applying them entirely to processing fees.
Outlook, Risks, and Contingencies
- Guidance: Management anticipates non-discretionary capital expenditures of approximately $750,000 over the next 12 months for software and equipment. No specific revenue or earnings guidance was provided.
- Legal Proceedings: The Company is involved in litigation against Cord Blood America, Inc. (CBAI) and Cryo-Cell de Mexico regarding a proposed asset acquisition that Cryo-Cell believes violates its license agreement. The court granted motions to dismiss the Company's initial claims in March 2011, but a hearing on a motion for rehearing is scheduled for September 7, 2011. Additionally, a new complaint for monetary damages (exceeding $75,000) was served on May 26, 2011; the amount is currently unquantifiable.
- Proxy Contest: A stockholder has initiated a proxy contest to nominate five directors for the 2011 annual meeting. Management expects this to result in significant additional legal and solicitation expenses, potentially impacting profitability and diverting management attention.
- Risk Factors: Key risks include increased competition from public cord blood banks, regulatory changes, the success of international licensing agreements, and the market acceptance of new stem cell technologies.
Investor Verification Checklist
- Proxy Contest Impact: Verify the estimated costs associated with the ongoing proxy contest and its potential effect on future operating margins.
- Licensee Income Volatility: Review the timing of up-front license fee installments from international partners (e.g., Nicaragua, Germany, Pakistan) to understand the variability in licensee income.
- Legal Exposure: Monitor the status of the litigation against CBAI/CCMEX and the new monetary damages complaint to assess potential financial liabilities.
- Revenue Recognition Policy: Confirm understanding of the retrospective accounting change and its impact on the comparability of current versus historical financial data.
- Saneron Investment: Review the status of the investment in Saneron CCEL Therapeutics, Inc., which is recorded at goodwill value ($684,000) and subject to impairment testing.